LUKAS SCHEIBLER - 10 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Research Officer
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol
APLS
Transactions as of
10 Feb 2023
Net transactions value
-$34,720
Form type
4
Filing time
14 Feb 2023, 15:44:52 UTC
Previous filing
30 Jan 2023
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability $34,720 -678 -1.1% $51.21 60,472 10 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares withheld for tax on a restricted stock unit release.